Abstract
From the laboratory and clinical studies on clindamycin-2-palmitate, the following results were obtained.
1. The sensitivity of 28 strains, isolated from pathological materials in our clinic, to clindamycin was estimated by the plate dilution method. Growth of Staphylococcus strains was inhibited 66.7% by 0.19 mcg/ml or less. Clindamycin was found to have almost complete cross resistance with lincomycin.
2. Single oral dose of 5 mg/kg produced serum concentration of an average level of 1.66 mcg/ml in 9 patients.
3. Tissue concentrations of clindamycin-2-palmitate in tonsils were measured. An average tissue level in 1 hour after oral administration of 5 mg/kg was 0.88 mcg/g, and that in 2 hours was 1.69 mcg/g.
4. Clindamycin-2-palmitate was clinically used to 14 cases of ear and throat infections, and it was effective in 85.7% of them.
